StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
BTIG Affirms bluebird bio (BLUE) at 'Buy' Following bb2121 Phase 1 Data in r/r Multiple Myeloma
December 1, 2016 7:51 AM
BTIG affirms bluebird bio, Inc. (Nasdaq: BLUE) with a Buy rating and $83 price target following strong results from bb2121 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Next Articles
bluebird bio (BLUE) PT Raised to $87 at Maxim Group
December 1, 2016 11:45 AM
bluebird bio (BLUE) PT Raised to $85 at Leerink Partners
December 1, 2016 11:26 AM
bluebird bio (BLUE) PT Raised 10% at Jefferies Following 'Impressive' Initial BCMA CAR-T Ph1 Data
December 1, 2016 7:47 AM
Wall Street little changed as bank rally pauses
December 1, 2016 7:45 AM
bluebird bio (BLUE) Reports Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product Candidate
November 30, 2016 5:28 PM
bluebird bio Announces Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product Candidate in Patients with Relapsed/Refractory Multiple Myeloma
November 30, 2016 5:27 PM
